BRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14
BRIEF-Trillium Therapeutics Inc Says Pfizer Voluntarily Withdrew Its Hart-Scott-Rodino Act Filing, And Expects To Re-File Such Form On Or About October 14
Oct 13 (Reuters) - Trillium Therapeutics Inc TRIL.TO :
路透10月13日电-Trillium Treateutics Inc TRIL.TO：
* TRILLIUM THERAPEUTICS - ON OCT 12, 2021, PFIZER VOLUNTARILY WITHDREW ITS HART-SCOTT-RODINO ACT FILING, AND EXPECTS TO RE-FILE SUCH FORM ON OR ABOUT OCTOBER 14
*延龄治疗公司-2021年10月12日，辉瑞公司自愿撤回了其Hart-Scott-Rodino ACT申报文件，预计将在10月14日左右重新提交此类表格
* TRILLIUM THERAPEUTICS INC - CO, PFIZER ARE WORKING COOPERATIVELY WITH APPLICABLE REGULATORY AUTHORITIES IN THEIR REVIEW OF PROPOSED ARRANGEMENT
*延龄治疗公司(Trillium Treateutics Inc-CO)、辉瑞(Pfizer)正在与适用的监管机构合作，审查拟议的安排
* TRILLIUM THERAPEUTICS INC - CO, PFIZER CONTINUE TO EXPECT TO CONSUMMATE ARRANGEMENT IN Q4 OF 2021 OR FIRST HALF OF 2022
*延龄治疗公司-CO，辉瑞公司继续预计在2021年第四季度或2022年上半年完成安排
Further company coverage: TRIL.TO
进一步的公司报道：TRIL.TO